Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
29.01
-0.18 (-0.62%)
At close: May 22, 2026, 4:00 PM EDT
28.75
-0.26 (-0.90%)
After-hours: May 22, 2026, 4:47 PM EDT
Rigel Pharmaceuticals Employees
As of December 31, 2025, Rigel Pharmaceuticals had 174 total employees, including 172 full-time and 2 part-time employees. The number of employees increased by 10 or 6.10% compared to the previous year.
Employees
174
Change (1Y)
10
Growth (1Y)
6.10%
Revenue / Employee
$1,722,799
Profits / Employee
$2,093,287
Market Cap
536.75M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 174 | 10 | 6.10% | 172 | 2 |
| Dec 31, 2024 | 164 | 17 | 11.56% | 162 | 2 |
| Dec 31, 2023 | 147 | -8 | -5.16% | 147 | 0 |
| Dec 31, 2022 | 155 | -10 | -6.06% | 155 | 0 |
| Dec 31, 2021 | 165 | -4 | -2.37% | 165 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Valneva SE | 674 |
| Ginkgo Bioworks Holdings | 485 |
| ProKidney | 231 |
| Prime Medicine | 146 |
| Kyverna Therapeutics | 130 |
| Assembly Biosciences | 73 |
| Tectonic Therapeutic | 60 |
RIGL News
- 4 days ago - Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress - PRNewsWire
- 6 days ago - Rigel Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 11 days ago - Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference - PRNewsWire
- 12 days ago - Rigel Pharmaceuticals price target raised to $81 from $69 at Citi - TheFly
- 13 days ago - H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’ - TheFly
- 13 days ago - Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu - TheFly
- 13 days ago - Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer - TheFly
- 13 days ago - Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug - Reuters